Navigation Links
Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013

SEATTLE, April 24, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter financial results on Thursday, May 2, 2013, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update, at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows:

Thursday, May 2
1:30 p.m. PT/4:30 p.m. ET/10:30 p.m. CET
1-877-941-6010 (domestic)
+1 480-629-9644 (international)

To access the live audio webcast or the subsequent archived recording, visit CTI's website, Webcast and telephone replays of the conference call will be available at approximately two hours after completion of the call. Callers can access the replay by dialing 1-800-358-3474 (domestic) or +1 303-590-3030 (international). The access code for the replay is #4615670. The telephone replay will be available until Thursday, May 9, 2013.

About Cell Therapeutics, Inc.

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit the company's website at

Media and Investor Contacts:

Cell Therapeutics, Inc.

Monique Greer
+1 206.272.4343

Ed Bell
+1 206.272.4345

In Europe

CTI Life Sciences Limited, Milan Branch

Laura Villa
Elena Bellacicca

T: +39 02 89659700
F: +39 02 89659719


SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
2. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
3. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
4. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
5. Galectin Therapeutics: Turning Atlanta into Americas Next Silicon Valley
6. Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
7. Aratana Therapeutics Adds To Drug Development Team
8. Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
9. Novira Therapeutics Completes $25 Million Series A Financing
10. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
11. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
Post Your Comments:
(Date:12/1/2015)... Mass. , Dec. 1, 2015 Researchers ... the McGovern Institute for Brain Research at MIT have ... that significantly cut down on "off-target" editing errors. The ... in the use of genome editing. Science ... that changing three of the approximately 1,400 amino acids ...
(Date:12/1/2015)... 2015 ... "2016 Europe Cell Surface Markers: Country ... Strategies, Opportunities for Suppliers--France, Germany, Italy, Spain, ... --> ) has announced the ... Surface Markers: Country Volume and Sales Forecasts, ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  Symic, a ... affect the extracellular matrix (ECM), today announced that it ... to advance the company,s pipeline, including its lead candidates ... Ventures and includes the participation by all existing major ... funding brings the total capital raised by Symic to ...
(Date:12/1/2015)... ) has ... Virology and Bacteriology Testing Market: Sales and ... Shares by Test, Innovative Technologies, Competitive Strategies, ... --> ) has announced the ... Bacteriology Testing Market: Sales and Volume Segment ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/27/2015)... YORK , Oct. 27, 2015 In ... major issues of concern for various industry verticals such ... is due to the growing demand for secure & ... in various ,sectors, such as hacking of bank accounts, ... for electronic equipment such as PC,s, laptops, and smartphones ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):